Is breast cancer population screening worth it?
For most women, participating in the population screening programme yields more benefit than cost, though this varies by age and risk profile. If you have dense breast tissue or a family history of breast cancer, discuss with your doctor whether supplemental testing makes sense for you.
Mammography screening has contributed to a reduction in breast cancer mortality of at least 20% over the past 30 years. That is a substantial effect, supported by multiple robust studies. For many women, participation is therefore worthwhile.
But the population screening programme has real drawbacks. Some women are unnecessarily recalled after a false-positive result, causing needless anxiety. There is also overdiagnosis: the detection of tumours that would never have caused symptoms and would never have needed treatment. Exactly how large this drawback is cannot easily be expressed in a single figure, but it does factor into the decision.
Whether you personally gain more than you lose depends on age, breast density and hereditary risk. Women with dense breast tissue may have cancers missed on standard mammography. For them, supplemental MRI is demonstrably the best option: in a large analysis of more than 260,000 women, MRI detected significantly more missed cancers than ultrasound or a 3D mammogram. MRI is now recommended for women with extremely dense breast tissue or an elevated familial risk.
An interesting development is the use of artificial intelligence to identify who would benefit from supplemental MRI. A randomised study showed that an AI risk analysis applied to mammography was nearly four times as efficient as conventional breast density measurement in selecting women for supplemental MRI. A British modelling study calculated that risk-stratified screening frequency (less screening for low-risk women, more for high-risk women) would both save costs and produce health gains. These are, however, still modelling calculations, not evidence of direct clinical benefit. And when it comes to AI as a replacement for the radiologist: a systematic review of 12 studies (over 130,000 women) showed that most AI systems were less accurate than a single radiologist, and all were less accurate than two radiologists reading together. AI as a screening tool is therefore not yet ready for independent use.
Finally, a point about access: women without health insurance participate less in the population screening programme, even though they may be precisely the ones who stand to benefit most from early detection.
Claims are based on multiple systematic reviews and a large meta-analysis (261,233 participants for MRI screening), a randomised study (ScreenTrustMRI), a decision-analytic model (NHS), and a systematic review on AI (BMJ, 131,822 women). The 20% mortality reduction is supported by multiple robust sources. Harms such as overdiagnosis are acknowledged but not expressed in hard figures in the available sources.
Can I inherit breast cancer in the family, and should I get tested?
Breast cancer can be hereditary, and if you recognise multiple cases in your family, it is sensible to discuss this with your GP or a genetic counsellor so you can determine whether testing is worthwhile.
Which cancer screenings are worthwhile, and from what age?
Colorectal cancer screening from age 50 and mammography from age 40 have the best evidence base for the average person; lung cancer screening is only relevant if you have a heavy smoking history. Other screenings are only worthwhile in the presence of specific risk factors or inherited conditions.
Should I, as a man, get tested for prostate cancer with the PSA test?
Whether the PSA test is worthwhile depends on your personal risk. Men aged 55 to 69 with an elevated risk, such as a family history or Black ethnicity, have the greatest reason to discuss this with their GP.
Does bowel cancer screening really help (less mortality)?
For people aged 45 to 75 with average risk, colorectal cancer screening is worthwhile and widely recommended. It demonstrably reduces the likelihood of developing colorectal cancer, although the evidence for short-term mortality reduction is less definitive than previously thought.
Does being overweight increase my risk of cancer, and if so, which types?
Excess weight increases your risk of at least 13 types of cancer, including uterine, colorectal, breast and liver cancer. Losing weight reduces that risk, although it remains unclear whether all methods of weight loss are equally effective for immune defence against cancer.
Does maintaining a healthy weight still help after a cancer diagnosis?
For most cancer types, a healthy weight after diagnosis is associated with better survival, but note: unintentional weight loss is a warning signal, and for a few cancer types the opposite pattern applies. Always discuss weight and muscle mass with your treating physician.